Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc.ELDN · Entity 6160 | Director | January 10, 2026 | January 16, 2026 |
| Emergent BioSolutions Inc.EBS · Entity 5902 | Director | April 30, 2026 | May 04, 2026 |
| RIGEL PHARMACEUTICALS INCRIGL · Entity 2423 | Director | May 19, 2021 | May 22, 2021 |
| Syndax Pharmaceuticals IncSNDX · Entity 4578 | Director | February 04, 2026 | February 06, 2026 |
| Urovant Sciences Ltd.UROV · Entity 140739 | Director · PEO;CEO/Urovant Sciences, Inc. | February 19, 2020 | February 21, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eledon Pharmaceuticals, Inc.
Report date January 10, 2026 · Filed January 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,575 |
Reported balance
After 2026-01-10 transaction · row 1
1 source rowRow 1 · 2026-01-10 · Exercise / conversion · Acquired 8,575 · Balance 8,575 F1: Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-01-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-10 · Exercise / conversion · Disposed 8,575 · Balance 0 F1: Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026.
Emergent BioSolutions Inc.
Report date April 30, 2026 · Filed May 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 96,294 |
Ending reported balance
After 2026-04-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-04-30 · Grant · Acquired 25,344 · Balance 111,775 F1: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the Reporting Person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Row 2 · 2026-04-30 · Sale · Disposed 15,481 · Balance 96,294 F2: Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated November 10, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on April 29, 2026. F3: The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $8.23 to $8.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.99 · Expires 2033-04-30 | Direct | 11,296 |
Reported balance
After 2026-04-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-30 · Grant · Acquired 11,296 · Balance 11,296 F4: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. F5: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the Reporting Person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.
F2: Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated November 10, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on April 29, 2026.
F3: The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $8.23 to $8.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.
F5: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.
RIGEL PHARMACEUTICALS INC
Report date May 19, 2021 · Filed May 22, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,000 |
Reported balance
After 2021-05-19 transaction · row 1
1 source rowRow 1 · 2021-05-19 · Grant · Acquired 25,000 · Balance 25,000 F1: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the reporting person's continuous service on the Company's Board of Directors. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.64 · Expires 2031-05-19 | Direct | 30,000 |
Reported balance
After 2021-05-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-05-19 · Grant · Acquired 30,000 · Balance 30,000 F2: The shares vest monthly over one (1) year from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the reporting person's continuous service on the Company's Board of Directors.
F2: The shares vest monthly over one (1) year from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors.
Syndax Pharmaceuticals Inc
Report date February 04, 2026 · Filed February 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 124,000 |
Reported balance
After 2026-02-04 transaction · row 1
1 source rowRow 1 · 2026-02-04 · Grant · Acquired 24,000 · Balance 124,000 F1: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control.
Urovant Sciences Ltd.
Report date February 19, 2020 · Filed February 21, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 199,680 |
Ending reported balance
After 2020-02-19 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2020-02-19 · Exercise / conversion · Acquired 180,000 · Balance 379,680 Row 2 · 2020-02-19 · Tax withholding · Disposed 104,788 · Balance 274,892 F1: Represents 53,119 shares surrendered to the Issuer in satisfaction of payment of exercise price and 51,669 shares surrendered to the Issuer in satisfaction of the payment of required withholding taxes in connection with the exercise of stock options. Row 3 · 2020-02-19 · Other · Disposed 75,212 · Balance 199,680 F2: Represents the sale of 75,212 shares of common stock to Sumitovant Biopharma Ltd., a subsidiary of Dainippon Sumitomo Pharma, in a privately-negotiated transaction. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.86 · Expires 2027-09-21 | Direct | 701,254 |
Reported balance
After 2020-02-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-02-19 · Exercise / conversion · Acquired 180,000 · Balance 701,254 F3: All of the shares underlying this option are vested and exercisable as of the date hereof. F4: Following the reported transactions, the Reporting Person beneficially owns options to purchase an aggregate of 1,416,166 common shares (inclusive of the options reported in Table II, Column 9 above). |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 53,119 shares surrendered to the Issuer in satisfaction of payment of exercise price and 51,669 shares surrendered to the Issuer in satisfaction of the payment of required withholding taxes in connection with the exercise of stock options.
F2: Represents the sale of 75,212 shares of common stock to Sumitovant Biopharma Ltd., a subsidiary of Dainippon Sumitomo Pharma, in a privately-negotiated transaction.
F3: All of the shares underlying this option are vested and exercisable as of the date hereof.
F4: Following the reported transactions, the Reporting Person beneficially owns options to purchase an aggregate of 1,416,166 common shares (inclusive of the options reported in Table II, Column 9 above).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 11, 2020 Filed Sep 16, 2020 00:10 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | GrantStock Option (Right to Buy) · Derivative | 5,907.15 | $0.00 Strike: $500.00 | $0.00 |
DisclosureSEC source: 0000899243-20-025166 · doc4.xml · derivative · entry 1 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,907.15 Underlying: Series X1 Convertible Preferred Stock · 5,907.15 shares Expires 2030-09-11 F1 · derivative.exercise_date: This option represents a right to purchase a total of 5,907.15 shares of the Issuer's Series X1 Convertible Preferred Stock, which will vest in equal monthly installments over two years, subject to the Reporting Person's continued service to the Issuer through each vesting date. The Reporting Person's ability to exercise the option will be subject to stockholder approval under Nasdaq Marketplace Rule 5635(c). F2 · derivative.underlying: Each share of Series X1 Convertible Preferred Stock will be convertible into 1,000 shares of Common Stock upon receipt of the requisite approval of the stockholders of the Issuer. Read SEC document |
| May 15, 2020 Filed May 16, 2020 00:55 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0001179110-20-006134 · edgar.xml · derivative · entry 1 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2030-05-15 F1 · derivative.exercise_date: The shares vest monthly over one (1) year from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 23:42 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | Exercise / conversionStock Option (Right to Buy) · Derivative | 180,000 | $0.00 Strike: $3.86 | $0.00 |
DisclosureSEC source: 0000899243-20-005517 · doc4.xml · derivative · entry 4 Katkin Keith · CIK 0001314596 · Director · PEO;CEO/Urovant Sciences, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 701,254 Underlying: Common Shares · 180,000 shares Expires 2027-09-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of the shares underlying this option are vested and exercisable as of the date hereof. F4 · balance_after: Following the reported transactions, the Reporting Person beneficially owns options to purchase an aggregate of 1,416,166 common shares (inclusive of the options reported in Table II, Column 9 above). Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 23:42 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | OtherCommon Shares | 75,212 | $13.08 | $983,772.96 |
DisclosureSEC source: 0000899243-20-005517 · doc4.xml · nonDerivative · entry 3 Katkin Keith · CIK 0001314596 · Director · PEO;CEO/Urovant Sciences, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,680 F2 · kind: Represents the sale of 75,212 shares of common stock to Sumitovant Biopharma Ltd., a subsidiary of Dainippon Sumitomo Pharma, in a privately-negotiated transaction. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 23:42 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | Tax withholdingCommon Shares | 104,788 | $13.08 | $1,370,627.04 |
DisclosureSEC source: 0000899243-20-005517 · doc4.xml · nonDerivative · entry 2 Katkin Keith · CIK 0001314596 · Director · PEO;CEO/Urovant Sciences, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,892 F1 · kind: Represents 53,119 shares surrendered to the Issuer in satisfaction of payment of exercise price and 51,669 shares surrendered to the Issuer in satisfaction of the payment of required withholding taxes in connection with the exercise of stock options. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 23:42 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | Exercise / conversionCommon Shares | 180,000 | $3.86 | $694,800.00 |
DisclosureSEC source: 0000899243-20-005517 · doc4.xml · nonDerivative · entry 1 Katkin Keith · CIK 0001314596 · Director · PEO;CEO/Urovant Sciences, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 379,680 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:35 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $9.47 | $0.00 |
DisclosureSEC source: 0001562180-20-001231 · primarydocument.xml · derivative · entry 1 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2030-02-12 Read SEC document |
| January 07, 2020 Filed Jan 9, 2020 21:33 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | GrantCommon Shares | 199,680 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-000884 · doc4.xml · nonDerivative · entry 1 Katkin Keith · CIK 0001314596 · Director · PEO;CEO/Urovant Sciences, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,680 F1 · shares: 25% of the Restricted Stock Units shall vest on January 7, 2021; the remaining Restricted Stock Units vest in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 22:01 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | Exercise / conversionStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $3.86 | $0.00 |
DisclosureSEC source: 0000899243-19-028937 · doc4.xml · derivative · entry 3 Katkin Keith · CIK 0001314596 · Director · PEO;CEO/Urovant Sciences, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 881,254 Underlying: Common Shares · 120,000 shares Expires 2027-09-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the total shares underlying the option vested and became exercisable on September 21, 2018; the remaining shares vest in 12 equal quarterly installments over the following three years, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 22:01 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | SaleCommon Shares | 120,000 | $12.78 | $1,533,600.00 |
DisclosureSEC source: 0000899243-19-028937 · doc4.xml · nonDerivative · entry 2 Katkin Keith · CIK 0001314596 · Director · PEO;CEO/Urovant Sciences, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $12.35 to $12.885. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This transaction was executed to minimize the potential impact of 280G excise tax, which may be triggered by the change of control resulting from the acquisition by Sumitomo Dainippon Pharma Co., Ltd. of Roivant Sciences Ltd.'s ownership interest in the Issuer. Following the reported transaction, the Reporting Person beneficially owns options to purchase an aggregate of 1,596,166 common shares. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 22:01 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | Exercise / conversionCommon Shares | 120,000 | $3.86 | $463,200.00 |
DisclosureSEC source: 0000899243-19-028937 · doc4.xml · nonDerivative · entry 1 Katkin Keith · CIK 0001314596 · Director · PEO;CEO/Urovant Sciences, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 11, 2019 Filed Jul 15, 2019 20:05 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $0.88 | $0.00 |
DisclosureSEC source: 0000899243-19-019600 · doc4.xml · derivative · entry 1 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-07-11 Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 13:00 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $7.88 | $0.00 |
DisclosureSEC source: 0001562180-19-003489 · primarydocument.xml · derivative · entry 1 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2029-06-10 Read SEC document |
| May 23, 2019 Filed May 24, 2019 21:23 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $2.02 | $0.00 |
DisclosureSEC source: 0001179110-19-006703 · edgar.xml · derivative · entry 1 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2029-05-23 F1 · derivative.exercise_date: The shares shall vest monthly over one (1) year from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors. Read SEC document |
| January 06, 2019 Filed Jan 8, 2019 22:22 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | GrantStock Option (Right to Buy) · Derivative | 350,250 | $0.00 Strike: $6.88 | $0.00 |
DisclosureSEC source: 0000899243-19-000777 · doc4.xml · derivative · entry 1 Katkin Keith · CIK 0001314596 · Director · PEO;CEO/Urovant Sciences, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,250 Underlying: Common Shares · 350,250 shares Expires 2029-01-06 F1 · derivative.exercise_date: 25% of the total shares underlying the option shall vest and become exercisable on January 2, 2020; the remaining shares vest in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 22:12 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | GrantStock Option (Right to Buy) · Derivative | 99,967 | $0.00 Strike: $13.65 | $0.00 |
DisclosureSEC source: 0001209191-18-055417 · doc4.xml · derivative · entry 1 Katkin Keith · CIK 0001314596 · Director · PEO;CEO-Urovant Sciences,Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,967 Underlying: Common Shares · 99,967 shares Expires 2028-10-14 F1 · derivative.exercise_date: 25% of the total shares underlying the option shall vest and become exercisable on October 1, 2019; the remaining shares vest in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date. Read SEC document |
| October 01, 2018 Filed Oct 4, 2018 01:04 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | GrantStock Option (Right to Buy) · Derivative | 200,250 | $0.00 Strike: $3.86 | $0.00 |
DisclosureSEC source: 0001209191-18-054162 · doc4.xml · derivative · entry 1 Katkin Keith · CIK 0001314596 · Director · PEO;CEO-Urovant Sciences,Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,250 Underlying: Common Shares · 200,250 shares Expires 2027-09-21 F1 · derivative.exercise_price: The exercise price of this option is $3.86. In light of the performance-based vesting condition of this option grant, such option grant was not reportable under Section 16 until the performance-based vesting condition was satisfied. The performance-based vesting condition was satisfied on October 1, 2018. F2 · derivative.exercise_date: Subject to the achievement of the Issuer's performance measurement referred to in Footnote (1) herein on October 1, 2018, 25% of the total shares underlying the option shall vest and become exercisable on October 1, 2019; the remaining shares vest in 12 equal quarterly installments over the following three years, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date. Read SEC document |
| September 26, 2018 Filed Sep 28, 2018 20:10 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | GrantStock Option (Right to Buy) · Derivative | 39,815 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052549 · doc4.xml · derivative · entry 1 Katkin Keith · CIK 0001314596 · Director · PEO;CEO-Urovant Sciences,Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,815 Underlying: Common Shares · 39,815 shares Expires 2028-09-25 F1 · derivative.exercise_date: 25% of the total shares underlying the option shall vest and become exercisable on September 26, 2019; the remaining shares vest in 12 equal quarterly installments over the following three years, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date. Read SEC document |
| June 13, 2018 Filed Jun 14, 2018 21:52 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | GrantStock Option (Right to Buy) · Derivative | 9,100 | $0.00 Strike: $6.18 | $0.00 |
DisclosureSEC source: 0000899243-18-016653 · doc4.xml · derivative · entry 1 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,100 Underlying: Common Stock · 9,100 shares Expires 2028-06-13 Read SEC document |
| May 23, 2018 Filed May 25, 2018 13:00 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $8.93 | $0.00 |
DisclosureSEC source: 0001562180-18-002682 · primarydocument.xml · derivative · entry 1 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2028-05-23 Read SEC document |
| May 17, 2018 Filed May 19, 2018 01:28 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $3.98 | $0.00 |
DisclosureSEC source: 0001179110-18-007149 · edgar.xml · derivative · entry 1 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-05-17 F1 · derivative.exercise_date: The shares shall vest monthly over one (1) year from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors. Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 21:01 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $9.63 | $0.00 |
DisclosureSEC source: 0001562180-18-000721 · primarydocument.xml · derivative · entry 1 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-02-08 F1 · derivative.exercise_date: 1/36th of the shares subject to the option shall vest monthly over a three-year period. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 20:05 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | GrantStock Option (Right to Buy) · Derivative | 36,000 | $0.00 Strike: $5.85 | $0.00 |
DisclosureSEC source: 0000899243-17-017760 · doc4.xml · derivative · entry 1 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2027-06-30 F1 · derivative.exercise_date: This option represents a right to purchase a total of 36,000 shares of the Issuer's Common Stock. The shares will vest ratably each quarter over three years beginning on June 30, 2017. Read SEC document |
| May 17, 2017 Filed May 19, 2017 15:26 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $13.58 | $0.00 |
DisclosureSEC source: 0001562180-17-002007 · primarydocument.xml · derivative · entry 1 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-05-17 Read SEC document |
| May 12, 2017 Filed May 12, 2017 22:01 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $2.61 | $0.00 |
DisclosureSEC source: 0001179110-17-007132 · edgar.xml · derivative · entry 1 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2027-05-12 F1 · derivative.exercise_date: The shares vest monthly over twelve (12) months from the date of grant. Read SEC document |
| March 29, 2017 Filed Mar 31, 2017 20:46 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $13.78 | $0.00 |
DisclosureSEC source: 0001562180-17-001365 · primarydocument.xml · derivative · entry 1 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-03-29 F1 · derivative.exercise_date: 1/36th of the shares subject to the option shall vest monthly over a three-year period. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.